Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis

Sasaki, Takeshi; Onishi, Takehisa; Hoshina, Akira

doi:10.1038/pcan.2011.14

Cited by 76 publications

(94 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15,21,22 In our study, PSA was also identified as having an insignificant effect on survival. Regarding such cases, Sasaki et al 23 provided a promising opinion that nadir PSA levels and the time to PSA nadir following primary androgen deprivation therapy might be the most important early predictors for longer survival in PCa patients with bone metastases. Saeter et al 24 found that the survival of patients with soft tissue or non-regional lymph node metastases was similar to those patients presenting with skeletal metastases only, but few studies have discussed the prognostic value of these factors.…”

Section: Discussionmentioning

confidence: 99%

Clinical features and prognostic factors for patients with bone metastases from prostate cancer

He¹,

Zeng²,

Yang³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

To identify the clinical features and independent predictors of survival in patients with bone metastases from prostate cancer (PCa). We retrospectively analysed 115 PCa patients with bone metastases between 1997 and 2009. The overall survival rate after bone metastases was calculated using the Kaplan-Meier method. The prognostic factors were identified by univariate analysis using a log-rank test and by multivariate analysis using Cox proportional hazards regression models. The follow-up rate was 100%, the follow-up cases during 1, 3 and 5 years were 103, 79 and 55, respectively. The 1-, 3-and 5-year survival rates were 89.1%, 60.9% and 49.8%, respectively, with a median survival time of 48.5 months for patients with bone metastases from PCa. In univariate analysis, age, Gleason score, clinical stage, the number of bone lesions, alkaline phosphatase (ALP) level, invasion of neighbouring organs and non-regional lymph node metastases were correlated with prognosis. By multivariate analysis using Cox regression, ALP level, Gleason score and non-regional lymph node metastases were independent prognostic factors. These prognostic factors will help us to determine the appropriate dose and fraction of radiotherapy for these patients. INTRODUCTIONProstate cancer (PCa), the most common carcinoma in the industrialised world, has had increasing incidence in China. It is the only solid tumour diagnosed with its first recurrence as bone metastases instead of visceral metastases. 1 The bones are among the most frequent distant metastatic sites for PCa, occurring in 85%-100% patients. 2 Some studies 3-5 have been undertaken to identify prognostic factors for PCa, but less research has been undertaken on bone metastases regularity, especially on the Chinese mainland.In this retrospective study, 115 cases of PCa with bone metastases were collected, and the clinical features and main prognostic factors, including age, Gleason score, stage, endocrine therapy, castration, radiotherapy, number of bone lesions, prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels, neighbouring organ metastases, regional and remote lymph node metastases, surrounding parenchyma invaded and other visceral metastases were analysed to determine treatment strategies and to predict the reactions of the patients to treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical features and prognostic factors for patients with bone metastases from prostate cancer

He¹,

Zeng²,

Yang³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

show abstract

“…Xenografts without fibroblasts contained 5 ×10 5 LNCaP cells. Xenografts with fibroblasts were prepared by mixing 2.5 × 10 5 LNCaP cells and 2.5 × 10 5 fibroblasts in suspension.…”

Section: Animal Studiesmentioning

confidence: 99%

“…Prolonged serum PSA decline after ADT strongly indicated disease progression in patients with advanced PCa. 5,6 Several recent studies have also demonstrated that longer time to PSA nadir after ADT can predict favorable progression-free survival and overall survival in various hormone-naive patient populations based on large, multicenter investigations. 3,7,8 Thus, surprisingly, a rapid decline in PSA expression after ADT strongly appears to indicate more aggressive disease.…”

mentioning

confidence: 99%

“…In our previous work, we found that PSA kinetics after ADT were not an accurate prognostic marker when we regarded serum PSA levels after ADT as the number of viable cancer cells. 5,6 PSA is an androgen-regulated serine protease and member of the tissue kallikrein family of proteases. 9 Transcription of the PSA gene is normally regulated by androgens through the androgen receptor (AR).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer

Sasaki

Ishii

Iwamoto

et al. 2016

Laboratory Investigation

View full text Add to dashboard Cite

“…Similar to the previous study, 16 patients with lymph node metastasis were also included. In another retrospective study, 18 a high PSA nadir level was shown to be associated with shorter OS in a homogeneous group of patients with metastatic prostate cancer prescribed ADT. Nonetheless only 87 patients were included in the study.…”

Section: Discussionmentioning

confidence: 93%

Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy

Wong

et al. 2015

Hong Kong Med J

View full text Add to dashboard Cite

Objective:To investigate the impact of skeletalrelated events on survival in patients with metastatic prostate cancer prescribed long-term androgen deprivation therapy.Methods: This historical cohort study was conducted in two hospitals in Hong Kong. Patients who were diagnosed with metastatic prostate cancer and prescribed androgen deprivation therapy between January 2006 and December 2011 were included. Details of skeletal-related events and mortality were examined. Results:The median follow-up was 28 (range, 1-97) months. Of 119 patients, 52 (43.7%) developed skeletal-related events throughout the study, and the majority received bone irradiation for pain control. The median actuarial overall survival and cancer-specific survival for patients with skeletalrelated events were significantly shorter than those without skeletal-related events (23 vs 48 months, P=0.003 and 26 vs 97 months, P<0.001, respectively). Multivariate analysis revealed that the adjusted hazard ratio of presence of skeletal-related events on overall and cancer-specific survival was 2.73 (95% confidence interval, 1.46-5.10; P=0.002) and 3.92 (95% confidence interval, 1.87-8.23; P<0.001), respectively. A prostate-specific antigen nadir of >4 ng/mL was an independent poor prognostic factor for overall and cancer-specific survival after development of skeletal-related events (hazard ratio=10.42; 95% confidence interval, 2.10-51.66 and Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy IntroductionProstate cancer is the most common cancer diagnosed in men in developed countries. In the United States, there were 240 890 estimated new cases in 2011, accounting for 29% of all new cancers in men and over 33 000 deaths. 1 According to the Hong Kong Cancer Registry in 2012, prostate cancer was the third most common cancer in men. 2 New knowledge added by this study • Skeletal-related events (SREs) in patients with metastatic prostate cancer significantly worsen their prognosis.• The prevalence of SREs in patients with metastatic prostate cancer is high. Implications for clinical practice or policy • Medications such as bisphosphonate therapy and receptor activator for nuclear factor κB ligand inhibitor should be considered to prevent SREs in patients with metastatic prostate cancer.Hong Kong Med J 2016;22:106-15

show abstract

Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis

Cited by 76 publications

References 20 publications

Clinical features and prognostic factors for patients with bone metastases from prostate cancer

Clinical features and prognostic factors for patients with bone metastases from prostate cancer

Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer

Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy

Contact Info

Product

Resources

About